AMRI : Summary for Albany Molecular Research, Inc. - Yahoo Finance

U.S. Markets closed

Albany Molecular Research, Inc. (AMRI)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.67+0.44 (+2.71%)
At close: 4:00 PM EST
People also watch:
ARQLARRYALKSENZNANIK
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close16.23
Open16.41
Bid0.00 x
Ask0.00 x
Day's Range16.41 - 16.79
52 Week Range12.45 - 20.59
Volume113,326
Avg. Volume235,869
Market Cap600.39M
Beta1.12
PE Ratio (TTM)-11.41
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Albany Molecular Research, Inc. (AMRI) A Good Stock To Buy?
    Insider Monkey6 hours ago

    Is Albany Molecular Research, Inc. (AMRI) A Good Stock To Buy?

    Looking for high-potential stocks? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 7.6% in the 12 months ending November 21, with […]

  • Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : December 2, 2016
    Capital Cube4 days ago

    Albany Molecular Research, Inc. breached its 50 day moving average in a Bearish Manner : AMRI-US : December 2, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Albany Molecular Research, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day ... Read more (Read more...)

  • PR Newswire7 days ago

    AMRI Announces API Supply Agreement with Shire

    ALBANY, N.Y., Nov. 29, 2016 /PRNewswire/ -- AMRI (AMRI) announced today that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, Inc. which product has been in AMRI's portfolio through the required stages of development.  Shire plc, is a leading global biotechnology company focused on developing and marketing innovative medicines for patients with rare diseases and other highly specialized conditions. The terms of the agreement are confidential.  This is the second such multi-year agreement between AMRI and Shire, as AMRI has also been supplying a key neuroscience product to Shire. "This agreement builds on the long-standing development and manufacturing relationship between Shire and AMRI," said William S. Marth, President and CEO of AMRI.